Olopatadine: Difference between revisions
| [unchecked revision] | [unchecked revision] |
MDElliottMD (talk | contribs) parser-claude batch MedTemplate pre-fill, Top 300 #269 |
MDElliottMD (talk | contribs) home-claude category backfill (parser-claude gap closure) |
||
| Line 21: | Line 21: | ||
== References == | == References == | ||
<references /> | <references /> | ||
[[Category:H1 receptor antagonists]] | |||
[[Category:Mast cell stabilizers]] | |||
[[Category:Ophthalmic antihistamines]] | |||
Latest revision as of 10:43, 23 May 2026
Olopatadine
Patanol, Pataday (ophthalmic, now OTC), Patanase (intranasal)
Experience
No personal reports yet
No clinical reports yet
Log in to add your own experience.
Problems
No problems yet. Be the first to suggest one.
+ Add a problemTitration strategies
No titration strategies yet. Be the first to suggest one.
Effects
No effects listed yet. Be the first to suggest one.
Relevant anecdote
No anecdotes yet. Share a relevant one.
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
Summary
Common uses
Allergic conjunctivitis (ophthalmic)0, Allergic rhinitis (intranasal Patanase)0
Pharmacy
Starting dose
Ophthalmic Pataday 0.7%: 1 drop in each eye once daily (24-hour formulation); Patanol 0.1% BID; intranasal Patanase 2 sprays/nostril BID
Preparations
0.1% (Patanol), 0.2% (Pataday once-daily original), 0.7% (Pataday 24-hour) ophthalmic solutions; 0.6% nasal spray
US FDA Max
Once daily (Pataday 0.7%); BID (other ophthalmic)
Pharmacology
Routes
Topical ophthalmic, intranasal
Onset
Symptom relief within 30-60 minutes
Duration
24 hours (0.7% formulation); 8-12 hours (lower-strength)
Half-life
~3 hours (systemic, when measurable; topical action dominates)[1]
Bioavailability
Topical with minimal systemic absorption[1]
Pregnancy
Generally considered safe; minimal systemic exposure.[citation needed]
Legal status
OTC (Pataday ophthalmic) and Rx-only (Patanase intranasal) in US
Purported mechanism
Olopatadine is a dual-acting agent: selective H1 receptor antagonism provides immediate symptom relief from existing mediator release, while mast cell membrane stabilization prevents further degranulation; the combination produces both fast and sustained ocular antiallergic effect.0 Minimal systemic absorption and the dual mechanism underlie its first-line role in seasonal allergic conjunctivitis. Comfort drops without preservatives are available for sensitive patients[1].
References
- ↑ 1.0 1.1 1.2 FDA Prescribing Information, Pataday (olopatadine HCl) ophthalmic solution, Alcon/Novartis, current revision. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/206276s003lbl.pdf